Marker Therapeutics, Inc.
MRKRHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, Marker Therapeutics, Inc. (MRKR) is listed under Biotechnology. The company carries a $16.0M market cap, placing it firmly in the micro-cap category. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-associated antigens and kill tumor cells expressing those targets.
Market Cap
$16.0M
Beta
1.53
P/E (TTM)
—
P/E (Fwd)
-1.81
EPS (TTM)
$-0.42
EPS (Fwd)
$-0.53
ROE
-76.9%
ROA
-40.5%
Cash
$11.3M
Total Debt
$0
Free CF
-$6.2M
52W Change
-6.8%
Annual Financials
Cash vs Debt
Where MRKR stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, MRKR finished 9.77% below its 150-day moving average ($1.33) and 14.89% below its 200-day moving average ($1.41). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MRKR overbought or oversold?
At the October 20, 2026 close, MRKR's RSI(14) was 56.9, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Marker Therapeutics, Inc. reports $11.3M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$6.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -76.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 1.53 means MRKR is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Marker Therapeutics, Inc.'s trajectory.